Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase NA 2Phase 1/2 2Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 91Neoplasms 75Prostatic Neoplasms 54Carcinoma, Hepatocellular 53Colorectal Neoplasms 49Leukemia, Myeloid, Acute 41Stomach Neoplasms 36Carcinoma, Non-Small-Cell Lung 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 29Pancreatic Neoplasms 27Lung Neoplasms 26Rectal Neoplasms 23Multiple Myeloma 21Hematologic Neoplasms 21Head and Neck Neoplasms 20Colonic Neoplasms 20Recurrence 19Lymphoma 19Leukemia 19Polycystic Ovary Syndrome 16Liver Neoplasms 14Esophageal Neoplasms 14Brain Neoplasms 13Myelodysplastic Syndromes 12Melanoma 12Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Motor Activity 11Fatigue 11

Interventions

Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Advanced Cancers × Clear all
NCT02597478 2021-02-09

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

M.D. Anderson Cancer Center

Phase 2/3 Completed
50 enrolled 14 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡